Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
13 sept. 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs
26 août 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...